{"symbol":"BMY","fiscalQuarter":"Q4-2021","reportDate":"2022-02-04","reportTime":"BMO","status":"reported","company":{"name":"Bristol-Myers Squibb Company","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/BMY/earnings/Q4-2021","postBrief":{"headline":"Bristol Myers Squibb Beats on EPS, Stock Up 1.44%","keyNumbers":[{"metric":"EPS","actual":"$1.83","expected":"N/A","surprise":"+0.11%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["Management expressed satisfaction with the EPS performance despite no revenue guidance.","They highlighted ongoing commitment to innovation and pipeline development."],"summary":"Overall, management conveyed a sense of cautious optimism regarding the company's performance. They emphasized the importance of their product pipeline and future growth potential."},"guidanceChanges":{"summary":"No guidance data is available for this quarter.","changes":[]},"whatItMeans":"Bristol Myers Squibb's earnings report shows a positive surprise in EPS, which likely contributed to the stock's 1.44% increase. The lack of revenue data leaves some uncertainty, but management's focus on innovation suggests they are positioning for future growth. Investors may view the EPS beat as a sign of resilience in a challenging market.","metaDescription":"Bristol Myers Squibb (BMY) Q4 2021 earnings: EPS beat by 0.11%. Stock up 1.44%. Full breakdown."}}